Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients

Share :
Published: 30 Sep 2024
Views: 276
Rating:
Save
Prof Salomon Manier - Hospital Center University De Lille, Lille, France

Prof Salomon Manier speaks to ecancer about the IMROZ frailty subgroup analysis at IMS 2024.

In the phase 3 IMROZ study in transplant-ineligible newly diagnosed multiple myeloma patients, isatuximab in combination with bortezomib, lenalidomide, and dexamethasone significantly improved progression-free survival and induced deep and sustained responses.

In this post-hoc subgroup analysis of IMROZ the efficacy of this regimen was tested across frail and non-frail subgroups.

Frailty scores at baseline were calculated based on age, modified Charlson Comorbidity Index calculated using medical history at baseline, and Eastern Cooperative Oncology Group performance status. Patients with a frailty score of 2 or higher were considered frail.

The results indicate the positive effects of isatuximab, bortezomib, lenalidomide, and dexamethasone in frail patients.

Prof Manier concludes by addressing the clinical implications of these findings.

Methodology of the IMROZ frailty subgroup analysis
Key results of the IMROZ frailty subgroup analysis
Clinical impact of the results from the IMROZ frailty subgroup analysis
Where does the study and this latest analysis sit in the treatment landscape?

 

ecancer's filming has been kindly supported by Sanofi through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.